The MedCan 2022 Industry Summit will help local companies accelerate their path to market through valuable insights into exporting, innovation and education. Industry experts will be presenting the latest scientific findings and breakthrough technologies and exploring the current challenges and opportunities around the likes of cultivating, manufacturing, New Zealand regulations, export, clinical trials, prescription and investment.
Day 1 – Industry Summit – 10 February
• Types of investment
• Trends
• Future of investments
This presentation will highlight the commercial potential for medicinal cannabis or hemp beyond its primary use by taking a ‘whole of resource’ approach. It will outline how the Bioresource Processing Alliance and research providers can help industry partners identify high-value opportunities from low-value biological resources.
• New Zealand gene bank
• different genetic technologies
• development of unique plants to those grown internationally
• Which traits to select- from disease resistance to cannabinoid profiles
• role of data management in a well-run breeding programme
Day 1 – Industry Summit – 10 February
| Time | Industry Stream | Science Stream |
|---|---|---|
| 11:15 | ||
| 11:20 | Industry Panel: Women in the medicinal cannabis industry Carmen Doran Chief Executive Officer, Helius Therapeutics Eva Neshat Founder and Chief Executive Officer, Elysian Pharmaceuticals & CannaPlus+ Zoë Reece Founder and CEO, Ora Pharm Dr Dottie Clower Chief Scientific Officer, Puro | Science Digging for seeds | Opportunities to run an internationally competitive structured breeding programme for New Zealand • New Zealand gene bank Dr Anna Campbell Consultant, AbacusBio |
| 11:50 | Science Understand the diseases that threaten NZ’s medicinal cannabis industry Kai Keli’iho’omalu Cultivation Manager, Helius Therapeutics | |
| 12:20 | Industry Investing in the future of the medical cannabis industry • Types of investment Kristen Lunman Co-Founder and GM, Hatch | Science Fireside chat: Helping talent navigate through the sector Carmen Doran Chief Executive Officer, Helius Therapeutics Ali Seyfoddin Associate Professor of Drug Delivery and Biological Engineering Deputy Head of School, School of Science, Auckland University of Technology |
| 12:50 | Industry Sustainable sector development through ‘whole plant’ utilisation This presentation will highlight the commercial potential for medicinal cannabis or hemp beyond its primary use by taking a ‘whole of resource’ approach. It will outline how the Bioresource Processing Alliance and research providers can help industry partners identify high-value opportunities from low-value biological resources. Andrew Cameron Principal Consultant, Callaghan Innovation Anna Yallop General Manager, Bioresource Processing Alliance | Science Fireside chat: Insights from the study on COVID for the MedCan industry Dr. Adele Hosseini, PhD Chief Scientific Officer, Bod Australia |